Welcome to PsychiatryAI.com: [PubMed] - Psychiatry AI Latest

P53 and VEGF are promising biomarkers for sorafenib efficacy in an experimental model of NASH-related HCC

Evidence

J Mol Histol. 2023 Aug 21. doi: 10.1007/s10735-023-10142-9. Online ahead of print.

ABSTRACT

The efficacy of systemic therapy for hepatocellular carcinoma (HCC) related to non-alcoholic steatohepatitis (NASH) is poorly understood. In this study we evaluated the effects of sorafenib based on the expression of molecular markers related to major hepatocarcinogenesis pathways and angiogenesis in a NASH-related HCC model. Forty male rats were submitted to NASH-HCC induction through the combination of a high-fat and choline deficient diet and diethylnitrosamine (100 mg/L) administration in the drinking water for 13 and 16 weeks. After the induction period, the rats received daily gavage administration of saline solution (control) or Sorafenib (5 mg/kg/day) for 3 weeks. Thereafter, the animals were euthanized and samples from liver nodules were collected for histopathological analysis and immunohistochemical assessment of HEP-PAR-1, glutamine-synthetase, VEGF, survivin, β-catenin and p53. A semi-quantitative score was used for VEGF, survivin and β-catenin analysis. For p53, the percentage of positive cells was determined. Results were processed by Wilcoxon’s test or Student’s t-test. Both protocols efficiently induced HCC, most of them being moderately to poorly differentiated. Sorafenib-treated animals showed a decreased expression of VEGF and p53 in HCCs generated at 13 weeks when compared to control animals (p = 0.03; p = 0.04, respectively). No significant difference in β-catenin and survivin were observed. There was a significant decrease in VEGF and p53 expression when comparing the two control groups (13 vs. 16 weeks, p < 0.01). p53 and VEGF are promising biomarkers for assessment of efficacy of Sorafenib, whereas survivin and β-catenin were not found useful. Decreased immunohistochemical expression of p53 and VEGF in the 16 week control group may indicate a different metabolic status of HCC.

PMID:37605073 | DOI:10.1007/s10735-023-10142-9

Document this CPD Copy URL Button

Google

Google Keep

LinkedIn Share Share on Linkedin

Estimated reading time: 5 minute(s)

Latest: Psychiatryai.com #RAISR4D Evidence

Cool Evidence: Engaging Young People and Students in Real-World Evidence

Real-Time Evidence Search [Psychiatry]

AI Research

P53 and VEGF are promising biomarkers for sorafenib efficacy in an experimental model of NASH-related HCC

Copy WordPress Title

🌐 90 Days

Evidence Blueprint

P53 and VEGF are promising biomarkers for sorafenib efficacy in an experimental model of NASH-related HCC

QR Code

☊ AI-Driven Related Evidence Nodes

(recent articles with at least 5 words in title)

More Evidence

P53 and VEGF are promising biomarkers for sorafenib efficacy in an experimental model of NASH-related HCC

🌐 365 Days

Floating Tab
close chatgpt icon
ChatGPT

Enter your request.

Psychiatry AI RAISR 4D System Psychiatry + Mental Health